Myasthenia Gravis and COVID-19: A Systematic Review and Meta-analysis.

IF 1 Q4 NEUROSCIENCES

Basic and Clinical Neuroscience Pub Date : 2024-03-01 DOI:10.32598/bcn.2023.4360.5

Amirhossein Nafari, Seyedpouzhia Shojaei, Reza Jalili Khoshnood, Mahsa Ghajarzadeh, Arash Tafreshinejad, Saeid Safari, Omid Mirmosayyeb

{"title":"Myasthenia Gravis and COVID-19: A Systematic Review and Meta-analysis.","authors":"Amirhossein Nafari, Seyedpouzhia Shojaei, Reza Jalili Khoshnood, Mahsa Ghajarzadeh, Arash Tafreshinejad, Saeid Safari, Omid Mirmosayyeb","doi":"10.32598/bcn.2023.4360.5","DOIUrl":null,"url":null,"abstract":"Introduction: Patients with myasthenia gravis (MG), an autoimmune disease affecting the neuromuscular junction, exhibits varying rates of COVID-19 infection across different studies. This systematic review and meta-analysis aim to estimate the pooled prevalence of COVID-19 infection in individuals with MG.Methods: We systematically searched PubMed, Scopus, EMBASE, Web of Science, Google Scholar, and gray literature, including references to the research published before October 2021. The total number of participants, the first author, the publication year, the country of origin, the number of MG patients, their symptoms, hospitalization rates, and deaths were all extracted as study data.Results: Our literature search yielded 253 articles, of which 75 remained after removing duplicates. Finally, 18 articles were included in the meta-analysis. The pooled prevalence of COVID-19 infection in MG cases was found to be 2% (95% CI, 1%, 3%; I2=85%, P<0.001). Additionally, the pooled prevalence of hospitalization among those with COVID-19 infection was 43% (95% CI, 26%, 60%; I2=97.6%; P<0.001), and the pooled prevalence of MG exacerbation was 33% (95% CI, 20%, 46%; I2=92.6%; P<0.001).Conclusion: In summary, this systematic review and meta-analysis reveal that the pooled prevalence of COVID-19 infection in individuals with MG is 2%.","PeriodicalId":8701,"journal":{"name":"Basic and Clinical Neuroscience","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367215/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic and Clinical Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/bcn.2023.4360.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Patients with myasthenia gravis (MG), an autoimmune disease affecting the neuromuscular junction, exhibits varying rates of COVID-19 infection across different studies. This systematic review and meta-analysis aim to estimate the pooled prevalence of COVID-19 infection in individuals with MG.

Methods: We systematically searched PubMed, Scopus, EMBASE, Web of Science, Google Scholar, and gray literature, including references to the research published before October 2021. The total number of participants, the first author, the publication year, the country of origin, the number of MG patients, their symptoms, hospitalization rates, and deaths were all extracted as study data.

Results: Our literature search yielded 253 articles, of which 75 remained after removing duplicates. Finally, 18 articles were included in the meta-analysis. The pooled prevalence of COVID-19 infection in MG cases was found to be 2% (95% CI, 1%, 3%; I²=85%, P<0.001). Additionally, the pooled prevalence of hospitalization among those with COVID-19 infection was 43% (95% CI, 26%, 60%; I²=97.6%; P<0.001), and the pooled prevalence of MG exacerbation was 33% (95% CI, 20%, 46%; I²=92.6%; P<0.001).

Conclusion: In summary, this systematic review and meta-analysis reveal that the pooled prevalence of COVID-19 infection in individuals with MG is 2%.

查看原文本刊更多论文

肌无力与 COVID-19：系统回顾与元分析》。

简介：重症肌无力（MG）是一种影响神经肌肉接头的自身免疫性疾病，在不同的研究中，患者的COVID-19感染率各不相同。本系统综述和荟萃分析旨在估算 COVID-19 在重症肌无力患者中的总体感染率：我们系统地检索了 PubMed、Scopus、EMBASE、Web of Science、Google Scholar 和灰色文献，包括 2021 年 10 月之前发表的研究参考文献。研究数据包括参与者总人数、第一作者、发表年份、来源国、MG 患者人数、症状、住院率和死亡人数：我们的文献检索共获得 253 篇文章，去除重复文章后，剩下 75 篇。最后，18 篇文章被纳入荟萃分析。MG病例中COVID-19感染的汇总患病率为2%（95% CI，1%，3%；I2=85%，P2=97.6%；P2=92.6%；PC结论：MG病例中COVID-19感染的汇总患病率为2%（95% CI，1%，3%；I2=85%，P2=97.6%；P2=92.6%）：综上所述，本系统综述和荟萃分析显示，COVID-19 在 MG 患者中的总感染率为 2%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Basic and Clinical Neuroscience NEUROSCIENCES-

CiteScore

2.60

自引率

0.00%

发文量

审稿时长

4 weeks

期刊介绍： BCN is an international multidisciplinary journal that publishes editorials, original full-length research articles, short communications, reviews, methodological papers, commentaries, perspectives and “news and reports” in the broad fields of developmental, molecular, cellular, system, computational, behavioral, cognitive, and clinical neuroscience. No area in the neural related sciences is excluded from consideration, although priority is given to studies that provide applied insights into the functioning of the nervous system. BCN aims to advance our understanding of organization and function of the nervous system in health and disease, thereby improving the diagnosis and treatment of neural-related disorders. Manuscripts submitted to BCN should describe novel results generated by experiments that were guided by clearly defined aims or hypotheses. BCN aims to provide serious ties in interdisciplinary communication, accessibility to a broad readership inside Iran and the region and also in all other international academic sites, effective peer review process, and independence from all possible non-scientific interests. BCN also tries to empower national, regional and international collaborative networks in the field of neuroscience in Iran, Middle East, Central Asia and North Africa and to be the voice of the Iranian and regional neuroscience community in the world of neuroscientists. In this way, the journal encourages submission of editorials, review papers, commentaries, methodological notes and perspectives that address this scope.